Seroquel® combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia - SCORE
Study identifier:D1449L00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia.
Medical condition
schizophrenia
Phase
Phase 4
Healthy volunteers
No
Study drug
Quetiapine fumarate, conventional treatment for schizophrenia
Sex
All
Actual Enrollment
85
Study type
Interventional
Age
18 Years - 64 Years
Date
Study Start Date: 01 Sept 2005
Primary Completion Date: 01 Dec 2007
Study Completion Date: 01 Dec 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 quetiapine fumarate | Drug: Quetiapine fumarate oral Other Name: Seroquel |
| Active Comparator: 2 Conventional treatment for schizophrenia | Drug: conventional treatment for schizophrenia various standard therapies |
| Experimental: 3 quetiapine fumarate + Cognitive Remediation Therapy | Drug: Quetiapine fumarate oral Other Name: Seroquel |
Contacts
Investigators
Principal Investigator
Leif Lindström,
Västerås
